Prognostic Value of Inflammatory Cytokines in Predicting Hospital Readmissions in Heart Failure with Preserved Ejection Fraction

References

• Joseph P, Roy A, Lonn E, et al. Global variations in heart failure etiology, management, and outcomes. JAMA. 2023;329(19):1650–1661. doi:10.1001/jama.2023.5942
   PubMed Web of Science ®Google Scholar
• Metra M, Tomasoni D, Adamo M, et al. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the heart failure association of the European society of cardiology. Eur J Heart Fail. 2023;25(6):776–791. doi:10.1002/ejhf.2874
   PubMed Web of Science ®Google Scholar
• MacDonald BJ, Virani SA, Zieroth S, et al. Heart failure management in 2023: a pharmacotherapy- and lifestyle-focused comparison of current international guidelines. CJC Open. 2023;5(8):629–640. doi:10.1016/j.cjco.2023.05.008
   PubMedGoogle Scholar
• Desai AS, Lam C, McMurray J, et al. How to manage heart failure with preserved ejection fraction: practical guidance for clinicians. JACC Heart Fail. 2023;11(6):619–636. doi:10.1016/j.jchf.2023.03.011
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European society of intensive care medicine. Eur J Heart Fail. 2010;12(5):423–433. doi:10.1093/eurjhf/hfq045
   PubMed Web of Science ®Google Scholar
• Nolan M, Arnott C. Risks and burdens of unplanned heart failure readmissions: how to cut a Gordian knot? Heart Lung Circ. 2023;32(8):891–893. doi:10.1016/j.hlc.2023.08.002
   PubMed Web of Science ®Google Scholar
• Peh ZH, Dihoum A, Hutton D, et al. Inflammation as a therapeutic target in heart failure with preserved ejection fraction. Front Cardiovasc Med. 2023;10:1125687. doi:10.3389/fcvm.2023.1125687
   PubMed Web of Science ®Google Scholar
• Mooney L, Jackson CE, Adamson C, et al. Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction. Circ Heart Fail. 2023;16(4):e010051. doi:10.1161/CIRCHEARTFAILURE.122.010051
   PubMed Web of Science ®Google Scholar
• Segiet OA, Piecuch A, Mielanczyk L, et al. Role of interleukins in heart failure with reduced ejection fraction. Anatol J Cardiol. 2019;22(6):287–299. doi:10.14744/AnatolJCardiol.2019.32748
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–3639. doi:10.1093/eurheartj/ehad195
   PubMed Web of Science ®Google Scholar
• Chen Y, Zheng H, He Y. Prognostic significance of controlling nutritional status in older adults with heart failure with preserved ejection fraction: a prospective comparative study with other objective nutritional indices. Aging Clin Exp Res. 2023;35(6):1305–1315. doi:10.1007/s40520-023-02395-x
   PubMed Web of Science ®Google Scholar
• Zhou Q, Yang J, Tang H, et al. High triglyceride-glucose (TyG) index is associated with poor prognosis of heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2023;22(1):263. doi:10.1186/s12933-023-02001-4
   PubMed Web of Science ®Google Scholar
• Rego R, Pereira N, Pinto A, et al. Impact of a heart failure multidisciplinary clinic on the reduction of healthcare-related events and costs: the GEstIC study. Front Cardiovasc Med. 2023;10:1232291. doi:10.3389/fcvm.2023.1232291
   PubMed Web of Science ®Google Scholar
• Sotomi Y, Tamaki S, Hikoso S, et al. Pathophysiological insights into machine learning-based subphenotypes of acute heart failure with preserved ejection fraction. Heart. 2023. doi:10.1136/heartjnl-2023-323059
   PubMedGoogle Scholar
• Ye B, Bradshaw AD, Abrahante JE, et al. Left ventricular gene expression in heart failure with preserved ejection fraction-profibrotic and proinflammatory pathways and genes. Circ Heart Fail. 2023;16(8):e010395. doi:10.1161/CIRCHEARTFAILURE.123.010395
   PubMed Web of Science ®Google Scholar
• Paulus WJ. Unfolding Discoveries in Heart Failure. N Engl J Med. 2020;382(7):679–682. doi:10.1056/NEJMcibr1913825
   PubMed Web of Science ®Google Scholar
• Riehle C, Bauersachs J. Key inflammatory mechanisms underlying heart failure. Herz. 2019;44(2):96–106. doi:10.1007/s00059-019-4785-8
   PubMed Web of Science ®Google Scholar
• Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86(2):515–581. doi:10.1152/physrev.00024.2005
   PubMed Web of Science ®Google Scholar
• Tsioufis P, Theofilis P, Tsioufis K, et al. The impact of cytokines in coronary atherosclerotic plaque: current therapeutic approaches. Int J Mol Sci. 2022;23(24):15937. doi:10.3390/ijms232415937
   PubMed Web of Science ®Google Scholar
• Liu S, Ni S, Wang C, et al. Association of serum cytokines with coronary chronic total occlusion and their role in predicting procedural outcomes. Hellenic J Cardiol. 2023. doi:10.1016/j.hjc.2023.08.013
   Google Scholar
• Schiattarella GG, Rodolico D, Hill JA. Metabolic inflammation in heart failure with preserved ejection fraction. Cardiovasc Res. 2021;117(2):423–434. doi:10.1093/cvr/cvaa217
   PubMed Web of Science ®Google Scholar
• Schiattarella GG, Alcaide P, Condorelli G, et al. Immunometabolic Mechanisms of heart failure with preserved ejection fraction. Nat Cardiovasc Res. 2022;1(3):211–222. doi:10.1038/s44161-022-00032-w
   PubMedGoogle Scholar
• Wang H, Wu J, Ma L, et al. The role of interleukin −1 family in fibrotic diseases. Cytokine. 2023;165:156161. doi:10.1016/j.cyto.2023.156161
   PubMed Web of Science ®Google Scholar
• Del Buono MG, Bonaventura A, Vecchié A, et al. Pathogenic pathways and therapeutic targets of inflammation in heart diseases: a focus on Interleukin-1. Eur J Clin Invest. 2023. doi:10.1111/eci.14110
   PubMed Web of Science ®Google Scholar
• Abbate A, Toldo S, Marchetti C, et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020;126(9):1260–1280. doi:10.1161/CIRCRESAHA.120.315937
   PubMed Web of Science ®Google Scholar
• Liu H, Huang Y, Zhao Y, et al. Inflammatory macrophage interleukin-1β mediates high-fat diet-induced heart failure with preserved ejection fraction. JACC Basic Transl Sci. 2023;8(2):174–185. doi:10.1016/j.jacbts.2022.08.003
   PubMedGoogle Scholar
• Alogna A, Koepp KE, Sabbah M, et al. Interleukin-6 in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2023. doi:10.1016/j.jchf.2023.06.031
   PubMed Web of Science ®Google Scholar
• Sandip C, Tan L, Huang J, et al. Common variants in IL-17A/IL-17RA axis contribute to predisposition to and progression of congestive heart failure. Medicine. 2016;95(27):e4105. doi:10.1097/MD.0000000000004105
   PubMed Web of Science ®Google Scholar
• Baldeviano GC, Barin JG, Talor MV, et al. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res. 2010;106(10):1646–1655. doi:10.1161/CIRCRESAHA.109.213157
   PubMed Web of Science ®Google Scholar
• Li XF, Pan D, Zhang WL, et al. Association of NT-proBNP and interleukin-17 levels with heart failure in elderly patients. Genet Mol Res. 2016;15(2). doi:10.4238/gmr.15028014
   Web of Science ®Google Scholar
• Baumhove L, Bomer N, Tromp J, et al. Clinical characteristics and prognosis of patients with heart failure and high concentrations of interleukin-17D. Int J Cardiol. 2023:131384. doi:10.1016/j.ijcard.2023.131384
   PubMed Web of Science ®Google Scholar
• Manilall A, Mokotedi L, Gunter S, et al. Tumor necrosis factor-α mediates inflammation-induced early-stage left ventricular systolic dysfunction. J Cardiovasc Pharmacol. 2023;81(6):411–422. doi:10.1097/FJC.0000000000001428
   PubMed Web of Science ®Google Scholar
• Albar Z, Albakri M, Hajjari J, et al. Inflammatory markers and risk of heart failure with reduced to preserved ejection fraction. Am J Cardiol. 2022;167:68–75. doi:10.1016/j.amjcard.2021.11.045
   PubMed Web of Science ®Google Scholar
• Chan MM, Santhanakrishnan R, Chong JP, et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail. 2016;18(1):81–88. doi:10.1002/ejhf.431
   PubMed Web of Science ®Google Scholar
• Wang S, Wang Y, Luo M, et al. MMMELD-XI score is associated with short-term adverse events in patients with heart failure with preserved ejection fraction. Front Cardiovasc Med. 2021;8:650191. doi:10.3389/fcvm.2021.650191
   PubMed Web of Science ®Google Scholar